tirzepatide shortage update today ๐จ Alert: No Longer on FDA's Drug List As of October 2, 2024, the FDA has announced that the Tirzepatide shortage has been resolved. This means that all doses of Tirzepatide Shortage Ends - American
Description
Mounjaro uses Type 2 diabetes Mounjaro (tirzepatide) is FDA-approved to treat type 2 diabetes
GIP receptor agonism contributes additional insulinotropic activity in the post-prandial state and is associated in pre-clinical models with improvements in lipid handling and adipocyte function
The dosage is increased in 2.5 mg increments every 4 weeks until reaching the maximum tolerated dose
Many cheaper compounded versions were circulating, until FDA crackdowns began this spring
Cholesterol and Blood Pressure Doctors may also check: LDL cholesterol HDL cholesterol Triglycerides Blood pressure These markers help assess cardiometabolic risk and guide the overall treatment plan
Should I stop tirzepatide if I have side effects
